Tags

Type your tag names separated by a space and hit enter

Impact of weight loss on the metabolic syndrome.
Int J Obes (Lond) 2007; 31(9):1442-8IJ

Abstract

OBJECTIVE

To evaluate the effects of weight loss on the risk of having metabolic syndrome after 1 year of treatment with lifestyle modification alone, pharmacotherapy alone (sibutramine) or the combination of the two.

DESIGN

Randomized, controlled, 1-year clinical trial.

PATIENTS

One hundred and eighty women and 44 men, 18-65 years of age, with a body mass index of 30-45 kg/m(2), free of uncontrolled hypertension or type 1 or 2 diabetes.

INTERVENTION

Fifteen milligrams of sibutramine per day alone, lifestyle modification counseling alone, sibutramine plus lifestyle modification counseling or sibutramine plus brief lifestyle modification counseling.

MEASUREMENTS

The metabolic syndrome, as defined by the Adult Treatment Panel III.

RESULTS

Before treatment, 34.8% of the participants had the metabolic syndrome. Metabolic syndrome was more prevalent in Caucasians than African Americans (42.5 vs 20.3%; P<0.03), in males than females (65.1 vs 34.9%; P<0.002) and in older (>44 years) than younger (</=44 years) participants (47.5 vs 20.8%; P<0.0001). After 1 year of treatment, a moderate decrease in weight (8.0+/-8.7 kg) resulted in significant reductions in the prevalence of metabolic syndrome from 34.8 to 27.2% of all participants (P<0.02). Logistic regression analyses indicated that for each 1 kg of weight lost, the odds of metabolic syndrome were reduced by 8% (CI=0.89-0.97; P<0.003). Lifestyle modification either alone (P<0.04), or in combination with sibutramine (P<0.05), significantly reduced the prevalence of metabolic syndrome compared with sibutramine alone. The group effect was removed after controlling for weight loss.

CONCLUSIONS

The metabolic syndrome was prevalent in over one-third of obese individuals who sought weight loss treatment, and the prevalence differed by age, sex and ethnicity. Moderate weight loss markedly reduced the odds of metabolic syndrome in this sample.

Authors+Show Affiliations

Brown Medical School/The Miriam Hospital, Providence, RI, USA. sphelan@lifespan.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

17356528

Citation

Phelan, S, et al. "Impact of Weight Loss On the Metabolic Syndrome." International Journal of Obesity (2005), vol. 31, no. 9, 2007, pp. 1442-8.
Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond). 2007;31(9):1442-8.
Phelan, S., Wadden, T. A., Berkowitz, R. I., Sarwer, D. B., Womble, L. G., Cato, R. K., & Rothman, R. (2007). Impact of weight loss on the metabolic syndrome. International Journal of Obesity (2005), 31(9), pp. 1442-8.
Phelan S, et al. Impact of Weight Loss On the Metabolic Syndrome. Int J Obes (Lond). 2007;31(9):1442-8. PubMed PMID: 17356528.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of weight loss on the metabolic syndrome. AU - Phelan,S, AU - Wadden,T A, AU - Berkowitz,R I, AU - Sarwer,D B, AU - Womble,L G, AU - Cato,R K, AU - Rothman,R, Y1 - 2007/03/13/ PY - 2007/3/16/pubmed PY - 2007/12/6/medline PY - 2007/3/16/entrez SP - 1442 EP - 8 JF - International journal of obesity (2005) JO - Int J Obes (Lond) VL - 31 IS - 9 N2 - OBJECTIVE: To evaluate the effects of weight loss on the risk of having metabolic syndrome after 1 year of treatment with lifestyle modification alone, pharmacotherapy alone (sibutramine) or the combination of the two. DESIGN: Randomized, controlled, 1-year clinical trial. PATIENTS: One hundred and eighty women and 44 men, 18-65 years of age, with a body mass index of 30-45 kg/m(2), free of uncontrolled hypertension or type 1 or 2 diabetes. INTERVENTION: Fifteen milligrams of sibutramine per day alone, lifestyle modification counseling alone, sibutramine plus lifestyle modification counseling or sibutramine plus brief lifestyle modification counseling. MEASUREMENTS: The metabolic syndrome, as defined by the Adult Treatment Panel III. RESULTS: Before treatment, 34.8% of the participants had the metabolic syndrome. Metabolic syndrome was more prevalent in Caucasians than African Americans (42.5 vs 20.3%; P<0.03), in males than females (65.1 vs 34.9%; P<0.002) and in older (>44 years) than younger (</=44 years) participants (47.5 vs 20.8%; P<0.0001). After 1 year of treatment, a moderate decrease in weight (8.0+/-8.7 kg) resulted in significant reductions in the prevalence of metabolic syndrome from 34.8 to 27.2% of all participants (P<0.02). Logistic regression analyses indicated that for each 1 kg of weight lost, the odds of metabolic syndrome were reduced by 8% (CI=0.89-0.97; P<0.003). Lifestyle modification either alone (P<0.04), or in combination with sibutramine (P<0.05), significantly reduced the prevalence of metabolic syndrome compared with sibutramine alone. The group effect was removed after controlling for weight loss. CONCLUSIONS: The metabolic syndrome was prevalent in over one-third of obese individuals who sought weight loss treatment, and the prevalence differed by age, sex and ethnicity. Moderate weight loss markedly reduced the odds of metabolic syndrome in this sample. SN - 0307-0565 UR - https://www.unboundmedicine.com/medline/citation/17356528/Impact_of_weight_loss_on_the_metabolic_syndrome_ L2 - http://dx.doi.org/10.1038/sj.ijo.0803606 DB - PRIME DP - Unbound Medicine ER -